While the first commercial applications are taking place in Europe, scientists are continuously working to improve the efficacy and safety of CAR T cell therapy, to extend the therapy to other indications, and to find solutions for various challenges. CAR T pioneer Stanley Riddell (USA) said: “CAR T cells are now an established therapeutic in blood cancers, especially in B cell malignancies and myeloma, but we are at the infancy.”
Approaches to improve the efficacy (enhance proliferation and persistence of the CAR T cells) and to reduce toxicities include
Approaches to solve challenges such as production speed and costs include
Click on the blocks below to read more or to view webcasts.